Last reviewed · How we verify

Royal Free Hampstead NHS Trust — Portfolio Competitive Intelligence Brief

Royal Free Hampstead NHS Trust pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Saquinavir (Invirase®) Saquinavir (Invirase®) marketed HIV protease inhibitor HIV protease Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Baqiyatallah Medical Sciences University · 1 shared drug class
  2. Bristol-Myers Squibb · 1 shared drug class
  3. Community Research Initiative of New England · 1 shared drug class
  4. Drugs for Neglected Diseases · 1 shared drug class
  5. DualityBio Inc. · 1 shared drug class
  6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
  7. Far East Bio-Tec Co., Ltd · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Royal Free Hampstead NHS Trust:

Cite this brief

Drug Landscape (2026). Royal Free Hampstead NHS Trust — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/royal-free-hampstead-nhs-trust. Accessed 2026-05-17.

Related